For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$25.10
Thesis
Beam Therapeutics pioneers base editing, a precise single-letter approach to genetic correction that avoids double-strand breaks. Its pipeline spans both ex vivo and in vivo programs across genetic disease.
Catalysts
- BEAM-101 sickle cell data and progress
- In vivo base-editing program readouts
- Validation of precision editing versus nuclease approaches
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- May 7Financial resultsSEC
Beam Therapeutics filed 8-K (items 2.02,9.01) disclosing financial results.